Sanjay Mathew
Psychiatry · Houston, TXNPI 1023140332
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $113,700 of the $133,585 with a category attached, or 85.1%. 15 manufacturers reported payments, led by Janssen Research & Development, LLC at 45.2% of the total. Reporting peaked in 2019 at $63,909 and has fallen 93.2% since, to $4,337 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $1161.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$60K
- Boehringer Ingelheim$13K
- Merck$13K
- Livanova USA, Inc.$8K
- AbbVie$7K
- Sumitomo Pharma America, Inc.$7K
- plus $26K from 9 others
Across 79 payments — averaging $5915.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$177K
- Abbott$115K
- Sage Therapeutics, LLC$99K
- Merck$64K
- Boehringer Ingelheim Pharma GmbH & Co.kg$12K
What the payments were for
- Consulting fees$113,70085%
- Speaking & faculty fees$6,7505%
- Travel & lodging$10,2828%
- Food & beverage$2,8532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 33 | $60,395 |
| Boehringer Ingelheim | 13 | $12,741 |
| Merck | 17 | $12,513 |
| Livanova USA, Inc. | 7 | $8,342 |
| AbbVie | 15 | $7,163 |
| Sumitomo Pharma America, Inc. | 4 | $6,800 |
| Sage Therapeutics, LLC | 7 | $5,958 |
| Almatica Pharma LLC | 2 | $4,284 |
| Abbott | 9 | $3,883 |
| Greenwich Biosciences, Inc. | 1 | $3,000 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $2,100 |
| Neurocrine Biosciences, Inc. | 3 | $1,750 |
| Neos Therapeutics, LP | 1 | $1,725 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,700 |
| Sunovion Pharmaceuticals Inc. | 1 | $1,230 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,585 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Escitalopram Oxalate | 15 | $183 |
| Bupropion XlBupropion Hcl | 11 | $138 |
| Alprazolam | 15 | $104 |
| Lamotrigine | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.